Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) is a clinical-stage biopharmaceutical company focused on therapies built on its lipid nanocrystal (LNC) platform delivery technology. The Matinas news feed highlights developments around its lead antifungal candidate MAT2203, corporate strategy, and platform research, providing context for investors and observers tracking MTNB stock news.
Company news frequently covers clinical and medical updates for MAT2203, an oral formulation of amphotericin B being developed as a potential broad-spectrum treatment for invasive deadly fungal infections. Releases have described results from the Phase 2 EnACT study in HIV patients with cryptococcal meningitis, outcomes from the Compassionate/Expanded Use Access Program in patients with severe invasive fungal infections, and plans for the ORALTO Phase 3 registration trial in invasive aspergillosis. These items help readers understand how MAT2203 is performing in both controlled trials and real-world settings.
Matinas also issues corporate and strategic announcements, including updates on its strategic review, financing transactions such as preferred stock and warrant offerings, and responses to NYSE American listing notices. Board and governance news—such as the appointment of independent directors with expertise in biotechnology, healthcare, finance, and audit oversight, as well as director retirements and committee leadership changes—features prominently in the company’s communications.
In addition, the news stream includes scientific and platform data related to the LNC technology, such as in vitro and in vivo findings on LNC delivery of small oligonucleotides and chemotherapeutic agents, and conference presentations on intracellular delivery. Readers can use this page to follow how Matinas’ clinical programs, LNC platform research, and corporate actions evolve over time. For those monitoring MTNB, returning to this news page offers a centralized view of key press releases and event announcements.
Matinas BioPharma (NYSE: MTNB) announced a conference call on March 29, 2021, at 8:00 a.m. ET, to discuss its Q4 and full-year 2020 financial results. The call can be accessed by dialing (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll). Matinas is focused on developing therapeutics for unmet medical needs, including LYPDISO for hypertriglyceridemia and MAT2203 for cryptococcal meningitis in HIV patients. The company aims to solve drug delivery challenges through its proprietary lipid nanocrystal platform and has received funding from the Cystic Fibrosis Foundation to support MAT2501.
Matinas BioPharma (MTNB) announced CEO Jerome D. Jabbour will present a company overview at the Barclays Global Healthcare Conference on March 9, 2021, at 4:45 p.m. ET. The presentation will include investor meetings and will be available via a live webcast on the company’s investor relations page. Matinas focuses on developing innovative therapeutics, including LYPDISO for hypertriglyceridemia, MAT2203 for fungal infections, and MAT2501 for bacterial infections. The company aims to improve drug delivery through its proprietary lipid nanocrystal platform.
Matinas BioPharma Holdings announced the topline results for its ENHANCE-IT study, comparing LYPDISO™ against Vascepa®. Key findings showed a 46% relative increase in EPA levels and a 39% reduction in triglycerides (TGs) versus Vascepa, although the latter did not meet statistical significance. However, LYPDISO™ demonstrated significant reductions in several lipid and inflammatory markers in the per-protocol population. The study involved 100 participants and aimed to assess cardiovascular risk reduction potential.
Matinas BioPharma (NYSE: MTNB) announces CEO Jerome D. Jabbour will present a company overview at the ICR Conference 2021 on January 14, 2021, at 1:00 p.m. ET. He will also host virtual investor meetings. Investors can access a live webcast on the Company’s IR Calendar page, with a replay available for 90 days post-event. Matinas focuses on developing innovative therapeutics, including LYPDISO™, which targets hypertriglyceridemia, and MAT2203, an antifungal treatment currently in clinical trials. The Company’s technology aims to improve drug delivery and efficacy.
Matinas BioPharma Holdings (MTNB) announced that the FDA has conditionally accepted LYPDISO as the proposed brand name for its drug MAT9001, targeting cardiovascular and metabolic conditions. Additionally, the USPTO granted a Notice of Allowance for the trademark registration of LYPDISO. The company is preparing to submit a New Drug Application and expects topline data from its head-to-head study against Vascepa® in Q1 2021, with Phase 3 trials starting in H2 2021. These developments are significant for the potential commercialization of MAT9001.
Matinas BioPharma (MTNB) announced a collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to explore oral formulations of remdesivir using its Lipid Nanocrystal (LNC) delivery platform. This collaboration aims to develop formulations that might enhance drug delivery capabilities, particularly in combating COVID-19. Gilead Sciences will provide remdesivir, while Matinas will utilize NIAID’s preclinical services to conduct antiviral testing. The outcome of this partnership could provide significant advancements in oral drug administration for critical therapies.
Matinas BioPharma Holdings (MTNB) announced a Special Meeting of Stockholders on January 26, 2021, to seek approval for a potential reverse stock split of its common stock, within a range of 1-for-2 to 1-for-15. This initiative aims to enhance the stock's appeal to institutional investors and possibly facilitate inclusion in biotechnology and pharmaceutical indices, while positioning the company for an uplisting to major exchanges like NYSE or NASDAQ. The final split ratio will be determined by the Board after stockholder approval.
Matinas BioPharma Holdings, Inc. (MTNB) has appointed Hui Liu, Ph.D., M.B.A. as the new Chief Technology Officer. With over 20 years of experience in pharmaceutical development, particularly in lipid-based delivery systems, Dr. Liu aims to enhance the company's proprietary lipid nanocrystal (LNC) platform. Previously at Seqirus, he has expertise in lipid nanoparticle technologies for gene therapies. The company continues to advance its lead product, MAT9001, targeting hypertriglyceridemia, and is also developing MAT2203 and MAT2501 for serious infections and antibiotic treatments, respectively.
Matinas BioPharma (MTNB) has secured an award of up to $3.75 million from the Cystic Fibrosis Foundation to support the preclinical development of MAT2501, an oral formulation of amikacin targeting nontuberculous mycobacterial lung disease. The funding aims to accelerate MAT2501's advancement through essential studies towards Phase 2 trials. FDA designations as QIDP and Orphan Drug for MAT2501 offer potential marketing exclusivity for up to 12 years upon approval. The company is focused on addressing unmet medical needs in the treatment of chronic infections.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The company is set to host investor meetings and will have a pre-recorded fireside chat available on their website starting November 23, 2020. Matinas is focused on developing therapeutics for unmet medical needs, with its lead product candidate, MAT9001, targeting hypertriglyceridemia. Additionally, MAT2203, aimed at treating invasive fungal infections, is currently in a Phase 2 study for HIV-infected patients.